TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced Wednesday that it has successfully completed the Phase 1a dose-escalation clinical trial of its lead cancer therapeutic candidate, TTX-MC138.
It met its primary safety objectives and demonstrated durable disease stabilization in patients with advanced metastatic cancer.
The Boston-based clinical-stage company announced Wednesday that the drug candidate was well-tolerated, showing a complete absence of dose-limiting toxicities across all tested patient cohorts.
The positive data support advancing the therapeutic into Phase 2a clinical development.
Key Trial Findings & Patient Demographics
